-----BEGIN PRIVACY-ENHANCED MESSAGE----- Proc-Type: 2001,MIC-CLEAR Originator-Name: webmaster@www.sec.gov Originator-Key-Asymmetric: MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB MIC-Info: RSA-MD5,RSA, Opngmiu6CeDbBBBj3gME7YE8V2YtuN4hui+9uF5eFebaZVht7y7vphU1nV3z6o4Q 8W0TN4aElmtzx9MXjVhR/w== 0001169232-09-000943.txt : 20090217 0001169232-09-000943.hdr.sgml : 20090216 20090217102321 ACCESSION NUMBER: 0001169232-09-000943 CONFORMED SUBMISSION TYPE: SC 13G/A PUBLIC DOCUMENT COUNT: 2 FILED AS OF DATE: 20090217 DATE AS OF CHANGE: 20090217 GROUP MEMBERS: BRIAN J. STARK SUBJECT COMPANY: COMPANY DATA: COMPANY CONFORMED NAME: DEXCOM INC CENTRAL INDEX KEY: 0001093557 STANDARD INDUSTRIAL CLASSIFICATION: SURGICAL & MEDICAL INSTRUMENTS & APPARATUS [3841] IRS NUMBER: 330857544 FILING VALUES: FORM TYPE: SC 13G/A SEC ACT: 1934 Act SEC FILE NUMBER: 005-81357 FILM NUMBER: 09607983 BUSINESS ADDRESS: STREET 1: 6340 SEQUENCE DRIVE CITY: SAN DIEGO STATE: CA ZIP: 92121 BUSINESS PHONE: 8582000200 MAIL ADDRESS: STREET 1: 6340 SEQUENCE DRIVE CITY: SAN DIEGO STATE: CA ZIP: 92121 FILED BY: COMPANY DATA: COMPANY CONFORMED NAME: ROTH MICHAEL CENTRAL INDEX KEY: 0001010207 FILING VALUES: FORM TYPE: SC 13G/A BUSINESS ADDRESS: BUSINESS PHONE: 4142411810 MAIL ADDRESS: STREET 1: 10556 N PORT WASHINGTON RD CITY: MEQUON STATE: WI ZIP: 53092 SC 13G/A 1 d76165_sc13g-a.htm AMENDMENT NO. 2 TO SCHEDULE 13G

 

                                                                                                        

 

SECURITIES AND EXCHANGE COMMISSION

Washington, DC 20549

SCHEDULE 13G

(Rule 13d-102)

 

INFORMATION TO BE INCLUDED IN THE STATEMENTS FILED PURSUANT TO RULES 13d-1(b), (c), AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(b)

(Amendment No. 2)*

Dexcom, Inc.

(Name of Issuer)

Common Stock, par value $0.001 per share

(Title of Class of Securities)

           252131107           

(CUSIP Number)

                                           December 31, 2008                                       

(Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

 

o

Rule 13d-1(b)

 

x

Rule 13d-1(c)

 

o

Rule 13d-1(d)

*The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

The information required in the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

 

 



SCHEDULE 13G

CUSIP NO.252131107 

Page 2 of 6

 

 

1

 

NAMES OF REPORTING PERSONS

I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (Entities Only)

 

Michael A. Roth and Brian J. Stark, as joint filers pursuant to Rule 13d-1(k)

2

CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP        
                                                                                                                          (a) x
                                                                                                                          (b)
o

3

SEC USE ONLY

4

CITIZENSHIP OR PLACE OF ORGANIZATION

 

United States of America

NUMBER OF

 

SHARES

 

BENEFICIALLY

 

OWNED BY EACH

 

REPORTING

 

PERSON WITH

5

SOLE VOTING POWER

 

0

6

SHARED VOTING POWER

 

2,666,791 shares of Common Stock (See Item 4)

7

SOLE DISPOSITIVE POWER

 

0

8

SHARED DISPOSITIVE POWER


2,666,791 shares of Common Stock (See Item 4)

9

AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

 

2,666,791 shares of Common Stock (See Item 4)

10

CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES                

o

11

PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

 

8.7% (See Item 4)

12

TYPE OF REPORTING PERSON

 

IN

 



SCHEDULE 13G

CUSIP NO.252131107 

Page 3 of 6

 

 

Item 1(a).

Name of Issuer:

Dexcom, Inc. (the “Issuer”)

 

Item 1(b).

Address of Issuer's Principal Executive Offices:

 

5555 Oberlin Drive

 

San Diego, California 92121

 

Items 2(a),

(b) and (c).

Name of Persons Filing, Address of Principal Business Office and Citizenship:

This Amendment No. 2 to Schedule 13G is being filed on behalf of Michael A. Roth and Brian J. Stark, as joint filers (collectively, the "Reporting Persons").

The Reporting Persons have entered into a Joint Filing Agreement, a copy of which is filed with this Amendment No. 2 to Schedule 13G as Exhibit 1, pursuant to which the Reporting Persons have agreed to file this Amendment No. 2 to Schedule 13G jointly in accordance with the provisions of Rule 13d-1(k) of the Securities Exchange Act of 1934, as amended.

The principal business office of the Reporting Persons is 3600 South Lake Drive, St. Francis, WI 53235. The Reporting Persons are citizens of the United States of America.

Item 2(d).

Title of Class of Securities:

Common Stock, par value $0.001 per share (the "Common Stock")

 

Item 2(e).

CUSIP Number:

252131107

Item 3.

Not applicable

Item 4.

Ownership.

 

 

(a)

Amount beneficially owned:

2,666,791 shares of Common Stock* 

 

(b)

Percent of class:

Based on 29,787,706 shares of Common Stock of the Issuer outstanding as of November 5, 2008, as indicated in the Issuer’s Quarterly Report on Form 10-Q for the quarter ended September 30, 2007, and 769,231 shares of Common Stock issuable upon the conversion of certain bonds held by the Reporting Persons, the Reporting Persons hold approximately 8.7%* of the issued and outstanding Common Stock of the Issuer.

 



SCHEDULE 13G

CUSIP NO.252131107 

Page 4 of 6


 

(c)

Number of shares to which such person has:

 

(i)

Sole power to vote or direct the vote: 0

(ii)

Shared power to vote or direct the vote: 2,666,791 shares of Common Stock*

(iii)

Sole power to dispose or to direct the disposition of: 0

(iv)

Shared power to dispose of or direct the disposition of: 2,666,791 shares of Common Stock*

*The Reporting Persons beneficially own an aggregate of 2,666,791 shares of Common Stock. The foregoing amount of Common Stock and percentage ownership represent the combined indirect holdings of Michael A. Roth and Brian J. Stark.

All of the foregoing represents an aggregate of 2,666,791 shares of Common Stock held by Stark Master Fund Ltd. (“Stark Master”) and Stark Criterion Master Fund Ltd. (“Criterion Master”). The Reporting Persons direct the management of Stark Offshore Management LLC (“Stark Offshore”), which acts as the investment manager and has sole power to direct the management of Stark Master. The Reporting Persons direct the management of Stark Criterion Management LLC (“Stark Criterion”), which acts as the investment manager and has sole power to direct the management of  Criterion Master. As the Managing Members of Stark Offshore and Stark Criterion, the Reporting Persons possess voting and dispositive power over all of the foregoing shares. Therefore, for the purposes of Rule 13d-3 under the Exchange Act, the Reporting Persons may be deemed to be the beneficial owners of, but hereby disclaim such beneficial ownership of, the foregoing shares.

Item 5.

Ownership of Five Percent or Less of a Class.

Not applicable

Item 6.

Ownership of More than Five Percent on Behalf of Another Person.

Not applicable

Item 7.

Identification and Classification of the Subsidiary Which Acquired the Security Being Reported By the Parent Holding Company.

Not applicable

 

Item 8.

Identification and Classification of Members of the Group.

Not applicable

 



SCHEDULE 13G

CUSIP NO.252131107 

Page 5 of 6

 

Item 9.

Notice of Dissolution of a Group.

Not applicable

Item 10.

Certification.

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.

 



SCHEDULE 13G

CUSIP NO.252131107 

Page 6 of 6

 

SIGNATURE

 

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Dated:

February 17, 2009

 

/s/ Michael A. Roth                                       
Michael A. Roth

/s/ Brian J. Stark                                             

Brian J. Stark

 


EX-1 2 d76165_ex-1.htm JOINT FILING AGREEMENT

SCHEDULE 13G

 

CUSIP NO. 252131107

Exhibit 1

 

JOINT FILING AGREEMENT

 

In accordance with Rule 13d-1(k) under the Securities Exchange Act of 1934, as amended, the undersigned agree to the joint filing on behalf of each of them of a statement on Schedule 13G (including amendments thereto) with respect to 2,666,791 shares of Common Stock of Dexcom, Inc. and further agree that this Joint Filing Agreement shall be included as an exhibit to such joint filings.

 

The undersigned further agree that each party hereto is responsible for the timely filing of such Schedule 13G and any amendments thereto, and for the completeness and accuracy of the information concerning such party contained therein; provided, however, that no party is responsible for the completeness or accuracy of the information concerning any other party making the filing, unless such party knows or has reason to believe that such information is inaccurate.

 

IN WITNESS WHEREOF, the parties have executed this Joint Filing Agreement on February 17, 2009.

 

 

/s/ Michael A. Roth                                        
Michael A. Roth

/s/ Brian J. Stark                                               
Brian J. Stark

 

 

 

-----END PRIVACY-ENHANCED MESSAGE-----